Sellas Life Sciences Group Inc expected to post breakeven results a share - Earnings Preview
Brief: SELLAS Announces Executive Leadership Reorganization
Brief: SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
Brief: Sellas Life Sciences Expects 60 Mg Cohort To Be Analyzed In Q2
Brief: Sellas Life Sciences Announces Pricing Of $9.0 Million Public Offering
Brief: Sellas Life Sciences Says On Jan 2, Co & Cantor Fitzgerald Agreed To Terminate Controlled Equity Offering Sales Deal, Dated April 16, 2021
Brief: Sellas Provides Corporate Updates, Highlights Upcoming Milestones
Brief: 3D Medicines Updates On Exclusive License Agreement Between Co And Sellas Life Sciences
U.S. STOCKS ON THE MOVE-Cintas Corp, Carnival, Tri Pointe Homes
U.S. STOCKS ON THE MOVE-Emeren Group, Delta Airlines, Annexon Inc
Brief: Sellas Receives FDA Orphan Drug Designation For Sls009 For Treatment Of Peripheral T-Cell Lymphomas
U.S. STOCKS ON THE MOVE-CarMax, Spotify, Immunovant
Sellas rises on FDA's 'orphan' tag for blood cancer drug
Brief: Sellas Life Sciences Announces First Patients Enrolled In 60 Mg Dose Cohort In Phase 2A Clinical Trial Of SLS009 in Acute Myeloid Leukemia
Brief: Sellas Life Sciences Gets Positive Recommendation For Galinpepimut-S In Acute Myeloid Leukemia
Brief: Sellas Life Sciences Reaches Target Enrollment Ex-China In Phase 3 Regal Trial Of Galinpepimut-S In Acute Myeloid Leukemia
Brief: Sellas Life Sciences Receives Favorable FDA Type C Meeting Feedback On CMC Biologics License Application (BLA)
Brief: SELLAS Life Sciences Q3 Net Income USD -9.267 Million
U.S. STOCKS ON THE MOVE-SeaStar, SJW Group, Pinterest